Abstract
In this editorial, we emphasise the efficacy and challenges of using ketamine in treatment-resistant depression. We highlight the need for comprehensive evidence-based guidelines to manage the use of both licensed and off-licence ketamine formulations and discuss recent efforts by Beaglehole et al to develop ketamine guidelines in New Zealand. We finally advocate for national registries to monitor ketamine therapy, ensuring its responsible and effective use in the management of depression.
Original language | English |
---|---|
Article number | e107 |
Pages (from-to) | e107 |
Journal | BJPsych Open |
Volume | 10 |
Issue number | 3 |
DOIs | |
Publication status | Published - 10 May 2024 |